Key Biotec
Key Biotec has the exclusive license for Immunitor patented oral tableted therapeutics in North, Central and South America (excluding Canada), the EU (excluding UK), Australia and New Zealand (the “Territory”).
In Development
The GoldVault Project will introduce physical gold savings accounts to the global markets. Very similar to banks savings accounts, the difference being that the main currency of the GoldVault accounts is physical gold.
GoldVault is forecast to launch in 2021. Key Capital has a 20% interest in GoldVault and a further 10% under option.
Key Biotec has the exclusive license for Immunitor patented oral tableted therapeutics in North, Central and South America (excluding Canada), the EU (excluding UK), Australia and New Zealand (the “Territory”).
MaxCellLife develops and markets unique healthcare and antiaging products and supplements.
The GoldVault Project will introduce physical gold savings accounts to the global markets.